Source news

tradingview News

20 stories
tradingview

Alaunos Reports Preclinical ALN1003 Liver-Weight Signal After Body-Fat Adjustment

Alaunos reports ALN1003-treated mice showed lower liver weight after adjustment for body fat percentage in a 48-day DIO study.Key Highlights:Original SEC Filing: Alaunos Therapeutics, Inc. [ TCRT ] - 8-K - Jun. 29, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying i…

TradingView en
StocksUS
tradingview

Evommune reports EVO756 Phase 2b misses primary endpoint; halts CSU development

Evommune announced EVO756 Phase 2b in chronic spontaneous urticaria did not meet the primary endpoint and the company will cease development in CSU.Key Highlights:Original SEC Filing: Evommune, Inc. [ EVMN ] - 8-K - Jun. 29, 2026This is an AI-powered summary. It may contain inaccuracies. Consider v…

TradingView en
StocksUS
tradingview

United States Oil Fund posts $270.1M monthly loss, NAV rises to $1.731B

United States Oil Fund reported a net loss of $270,124,551 for May 2026 while ending month NAV rose to $1,731,312,535.Key Highlights:Original SEC Filing: United States Oil Fund, LP [ USO ] - 8-K - Jun. 29, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying important…

TradingView en
StocksUS
tradingview

Replimune Group FY 2026: Revenue $0 Net loss $(313.9)M — 10-K Summary

Replimune Group, Inc. reported a net loss of $(313.94)M for the fiscal year ended March 31, 2026, compared with a $(247.30)M net loss in fiscal 2025, as the company recorded no product revenue while investing in research, development and commercial readiness — 10-K Summary.Financial HighlightsBusin…

TradingView en
StocksUS
tradingview

Rocket Lab to Acquire Iridium; Lines Up $3.6 Billion Bridge Financing

Rocket Lab agreed to acquire Iridium in a cash-and-stock transaction and arranged financing to support the deal. Iridium shareholders will receive $27.00 in cash plus Rocket Lab stock determined by a VWAP-based exchange ratio ranging from 0.4000 to 0.2400, subject to customary approvals and conditi…

TradingView en
StocksUS